Increased Risk of Type 2 Diabetes in Alzheimer Disease

Diabetes

Volumn 53, Issue 2, 2004, Pages 474-481

  Janson, Juliette ^a   Laedtke, Thomas ^a   Parisi, Joseph E ^a   O'Brien, Peter ^a   Petersen, Ronald C ^a   Butler, Peter C ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; INSULIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID; BODY MASS INDEX; BRAIN; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISLETS OF LANGERHANS; MALE; MINNESOTA; PANCREAS; PREVALENCE; REGISTRIES; RISK FACTORS;

EID: 0842309993     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.2.474     Document Type: Article

References (72)

1. Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417-421, 1978
2. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159, 1988
3. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628-8632, 1987
4. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84:3881-3885, 1987
5. Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P: Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130:1-8, 1988
6. Braak H, Braak E: The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 15:6-31, 1992
7. Glenner GG, Wong CW: Alzheimer disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890, 1984
8. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245-4249, 1985
9. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K: Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4:2757-2763, 1985
10. Bahmanyar S, Higgins GA, Goldgaber D, Lewis DA, Morrison JH, Wilson MC, Shankar SK, Gajdusek DC: Localization of amyloid beta protein messenger RNA in brains from patients with Alzheimer disease. Science 237:77-80, 1987
11. Goedert M: Neuronal localization of amyloid beta protein precursor mRNA in normal human brain and in Alzheimer disease. EMBO J 6:3627-3632, 1987
12. Card JP, Meade RP, Davis LG: Immunocytochemical localization of the precursor protein for beta-amyloid in the rat central nervous system. Neuron 1:835-846, 1988
13. Shivers BD, Hilbich C, Multhaup G, Salbaum M, Beyreuther K, Seeburg PH: Alzheimer disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J 7:1365-1370, 1988
14. Van Broeckhoven C, Genthe AM, Vandenberghe A, Horsthemke B, Backhovens H, Raeymaekers P, Van Hul W, Wehnert A, Gheuens J, Cras P, et al: Failure of familial Alzheimer disease to segregate with the A4-amyloid gene in several European families. Nature 329:153-155, 1987
15. Tanzi RE, St George-Hyslop PH, Haines JL, Polinsky RJ, Nee L, Foncin JF, Neve RL, McClatchey AI, Conneally PM, Gusella JF: The genetic defect in familial Alzheimer disease is not tightly linked to the amyloid beta-protein gene. Nature 329:156-157, 1987
16. St George-Hyslop PH, Haines JL, Farrer LA, Polinsky R, Van Broeckhoven C, Goate A, McLachlan DR, Orr H, Bruni AC, Sorbi S, et al: Genetic linkage studies suggest that Alzheimer disease is not a single homogeneous disorder. FAD Collaborative Study Group. Nature 347:194-197, 1990
17. Wilson PW, Anderson KM, Kannel WB: Epidemiology of diabetes mellitus in the elderly: the Framingham Study. Am J Med 80(5A):3-9, 1986
18. Barnett AH, Eff C, Leslie RD, Pyke DA: Diabetes in identical twins: a study of 200 pairs. Diabetologia 20:87-93, 1981
19. Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD: Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia 30:763-768, 1987
20. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K: Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer disease. J Mol Biol 218:149-163, 1991
21. Glenner GG, Eanes ED, Wiley CA: Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. Biochem Biophys Res Commun 155:608-614, 1988
22. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756-760, 1994
23. Schubert D, Behl C, Lesley R, Brack A, Dargusch R, Sagara Y, Kimura H: Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A 92:1989-1993, 1995
24. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL: Human islet amyloid polypeptide expression in COS-1 cells: a model of intracellular amyloidogenesis. Am J Pathol 147:609-616, 1995
25. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediatesized toxic amyloid particles. Diabetes 48:491-498, 1999
26. Mirzabekov TA, Lin MC, Kagan BL: Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 271:1988-1992, 1996
27. Lashuel HA, Hartley D, Petre BM, Waltz T, Lansbury PT: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291, 2002
28. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish J, Kreutter D, Roche P, Butler PC: Treatment with growth hormone and dexamethasone in mice transgenic for human islet amyloid polypeptide causes islet amyloidosis and β-cell dysfunction. Diabetes 45:1094-1101, 1996
29. O'Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC: Islet amyloid polypeptide in human insulinomas: evidence for intracellular amyloidogenesis. Diabetes 43:329-336, 1994
30. Craig EA, Weissman JS, Horwich AL: Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell. Cell 78:365-372, 1994
31. Butler PC, Eberhardt NL, O'Brien TD. Islet amyloid polypeptide (IAPP) and insulin secretion. In Molecular Biology of Diabetes. Draznin B, LeRoith D, Eds. Totowa, NJ, Humana Press, 1994, p. 381-398
32. Schwartz P: Senile cerebral, pancreatic insular and cardiac amyloidosis. Trans N Y Acad Sci 27:393-413, 1965
33. Petersen RC, Kokmen E, Tangalos E, Ivnik RJ, Kurland LT: Mayo Clinic Alzheimer disease patient registry. Aging 2:408-415, 1990
34. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A: The Consortium to Establish a Registry for Alzheimer Disease (CERAD): Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer disease. Neurology 45:461-466, 1995
35. Betsholtz C, Christmansson L, Engstrom U, Rorsman F, Svensson V, Johnson KH, Westermark P: Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 251:261-264, 1989
36. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
37. Zhang S, Liu J, Saafi EL, Cooper GJ: Induction of apoptosis by human amylin in RINm5F islet beta-cells is associated with enhanced expression of p53 and p21WAF1/CIP1. FEBS Lett 455:315-320, 1999
38. Zhang S, Liu J, MacGibbon G, Dragunow M, Cooper GJ: Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. J Mol Biol 324:271-285, 2002
39. Bai JZ, Saafi EL, Shang S, Cooper GJ: Role of Ca2+ in apoptosis evoked by human amylin in pancreatic islet beta-cells. Biochem J 343:53-61, 1999
40. Tucker HM, Rydel RE, Wright S, Estus S: Human amylin induces "apoptotic" pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem 71:506-516, 1998
41. Laczko I, Holly S, Konya Z, Soos K, Varga J, Hollosi M, Penke B: Conformational mapping of amyloid peptides from the putative neurotoxic 25-35 region. Biochem Biophys Res Commun 205:120-126, 1994
42. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489, 2003
43. Blake MJ, Edelsman R, Feulner GJ, Nortone DD, Holbrook NJ: Stress-induced heat shock protein 70 expression in adrenal cortex: an adrenocorticotropic hormone-sensitive, age-dependent response. Proc Natl Acad Sci U S A 88:9873-9877, 1991
44. Finch CE, Cohen DM: Aging, metabolism, and Alzheimer disease: review and hypothesis. Exp Neurol 143:82-102, 1997
45. Yan SD, Stern D, Schmidt AM: What's the rage? The receptor for advanced glycation and end products (RAGE) and the dark side of glucose. Eur J Clin Invest 27:179-181, 1997
46. Sasaki N, Toki S, Chowei H, Saito T, Nakao N, Hayashi Y, Takeuchi M, Makita Z: Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer disease. Brain Res 888:256-262, 2001
47. Heitner J, Dickson D: Diabetics do not have increased Alzheimer-type pathology with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. Neurology 49:1306-1311, 1997
48. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, Foley D, Blanchette PL, Harris T, Chen R, White LR: Longitudinal association of vascular and Alzheimer dementias, diabetes, and glucose tolerance. Neurology 52:971-975, 1999
49. MacKight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer disease and vascular cognitive impairment in the Canadian study of health and aging. Dement Geriatr Cogn Disord 14:77-83, 2002
50. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M-R, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
51. Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z: Advanced glycation end products in Alzheimer disease and other neurodegenerative diseases. Am J Pathol 153:1149-1155, 1998
52. Mast H, Thompson JL, Lee SH, Mohr JP, Sacco RL: Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke 26:30-33, 1995
53. Tatemichi TK, Desmond DW, Paik M, Figueroa M, Gropen TI, Stern Y, Sano M, Remien R, Williams JB, Mohr JP, et al.: Clinical determinants of dementia related to stroke. Ann Neurol 33:568-575, 1993
54. Desmond DW, Tatemichi TK, Paik M, Stern Y: Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol 50:162-166, 1993
55. McCall AL: The impact of diabetes on the NCS. Diabetes 41:557-570, 1992
56. Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gibsen WH: Cerebral function in diabetes mellitus. Diabetologia 37:643-650, 1994
57. Langen SJ, Deary IJ, Hepburn DA, Frier BM: Cumulative cognitive impairment following recurrent severe hypoglycaemia in adult patients with insulin-treated diabetes mellitus. Diabetologia 34:337-344, 1991
58. Ott A, Stolk RP, van Harskamp F, Pols H, Hofman A, Breteler M: Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53:1937-1942, 1999
59. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ: The risk of dementia among persons with diabetes mellitus: a population based cohort study. Am J Epidemiol 145:301-308, 1997
60. Luchsinger JA, Tang M-X, Yaakov S, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635-641, 2001
61. Bucht G, Adolfsson R, Lithner F, Winblad B: Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 213:387-392, 1983
62. Wolf-Klein GP, Silversone FA, Brod MS, Levy A, Foley CJ, Termotto V, Breuer J: Are Alzheimer patients healthier? J Am Geriatr Soc 36:219-224, 1988
63. Ferini-Strambi L, Smirne S, Garanchini P, Pinto P, Franceschi M: Clinical and epidemiological aspects of Alzheimer disease with presenile onset: a case control study. Neuroepidemiology 9:39-49, 1990
64. Landin K, Blennow K, Wallin A, Gottfries C-G: Low blood pressure and blood glucose levels in Alzheimer disease: evidence for a hypometabolic disorder? J Intern Med 233:357-363, 1993
65. Mortel KF, Wood S, Pavol MA, Meyer JS, Rexer JL: Analysis of familial and individual risk factors among patients with ischemic vascular dementia and Alzheimer disease. Angiology 44:599-605, 1993
66. Neilson KA, Nolan JH, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW: Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer disease? J Am Geriatr Soc 44:1-8, 1996
67. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T: Alzheimer disease: a study of epidemiological aspects. Ann Neurol 15:335-341, 1984
68. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC: A case controlled study of Alzheimer disease in Australia. Neurology 40:1698-1707, 1990
69. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ: Clinical risk factors for Alzheimer disease: a population based case-control study. Neurology 41:1393-1397, 1991
70. Thorpe J, Widman LP, Wallin A, Beiswanger J, Blumenthal HT: Comorbidity of other chronic age-dependent diseases in dementia. Aging Clin Exp Res 6:159-166, 1994
71. Curb JD, Roderiquez BL, Petrovich H, Masaki KH, Burchfiel CM, Ross W, Chen R, Harris T, White LR: The relationship of diabetes and glucose tolerance to Alzheimer disease and vascular dementia (Abstract 488). Neurobiol Aging 17 (Suppl.):S122, 1996
72. The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197, 1997